# Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract

> **NCT03430895** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 15 (actual)

## Conditions studied

- Non-Transitional Cell Carcinoma of the Urothelial Tract
- Small Cell of the Bladder
- Adenocarcinoma of the Bladder
- Squamous Cell Carcinoma of the Bladder
- Metastatic Bladder Cancer

## Interventions

- **DRUG:** durvalumab and tremelimumab

## Key facts

- **NCT ID:** NCT03430895
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-31
- **Primary completion:** 2021-02-10
- **Final completion:** 2021-02-10
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2021-12-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03430895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03430895, "Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03430895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*